Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has shared an announcement.
Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced that both the company and its subsidiary, Innogen Technology, have subscribed to a structured deposit product from the Bank of Ningbo, totaling RMB105,000,000. This strategic move aims to maximize returns on idle funds through treasury management, leveraging low-risk wealth management products offered by reputable banks in the PRC. The subscription reflects the company’s ongoing strategy to optimize financial resources while ensuring sufficient working capital for operational needs.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a holding company primarily engaged in the research, development, and commercialization of pharmaceutical products. Its subsidiary, Innogen Technology, focuses on pharmaceutical research, development, and production.
Average Trading Volume: 874,715
Learn more about 2591 stock on TipRanks’ Stock Analysis page.